期刊
CHEMICAL COMMUNICATIONS
卷 58, 期 47, 页码 6693-6696出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2cc01759h
关键词
-
资金
- JSPS KAKENHI [17H06405]
- Grants-in-Aid for Scientific Research [17H06405] Funding Source: KAKEN
Protein kinase C (PKC) family is a potential target for treating cancer, Alzheimer's disease, and HIV infection. By screening compounds and designing analogues, we discovered a PKC ligand with remarkable isozyme selectivity.
The protein kinase C (PKC) family consists of ten isozymes and is a potential target for treating cancer, Alzheimer's disease, and HIV infection. Since known natural PKC agonists have little selectivity among the PKC isozymes, a new scaffold is needed to develop PKC ligands with remarkable isozyme selectivity. Taking advantage of machine-learning and computational chemistry approaches, we screened the PubChem database to select sesterterpenoids alotaketals as potential PKC ligands, then designed and synthesized alotaketal analogues with a different ring system and stereochemistry from the natural products. The analogue exhibited a one-order higher affinity for PKC alpha-C1A than for the PKC delta-C1B domain. Thus, this compound is expected to serve as the basis for developing PKC ligands with isozyme selectivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据